Sputum smear microscopy in the Xpert® MTB/RIF era

• Published in: The international journal of tuberculosis and lung disease 2019-01, Vol.23 (1), p.12-18
• Main Authors: Van Deun, A., Tahseen, S., Affolabi, D., Hossain, M. A., Joloba, M. L., Angra, P. K., Ridderhof, J. C., de Jong, B. C., Rieder, H. L.
• Format: Article
• Language: English
• Subjects: Afb Microscopy; Bacilli; Bacteriological Techniques - methods; Case Detection; Control Programme; Culture; Diagnosis; Diagnostic systems; Disease control; Humans; Microbial Sensitivity Tests; Microscopy; Microscopy - methods; Molecular Diagnostic Techniques - methods; Monitoring; Mycobacterium tuberculosis - genetics; Mycobacterium tuberculosis - isolation & purification; Patients; Rifampin - therapeutic use; Sensitivity and Specificity; Smear; Sputum; Sputum - microbiology; Transmitters; Tuberculosis; Tuberculosis, Multidrug-Resistant - drug therapy; Tuberculosis, Pulmonary - diagnosis; Tuberculosis, Pulmonary - transmission; Xpert® MTB/RIF
• ISSN: 1027-3719; 1815-7920
• DOI: 10.5588/ijtld.18.0553

A balanced perspective is advocated for the assessment and application of the most recent and the oldest diagnostic methods for pulmonary tuberculosis (TB)-the molecular Xpert® MTB/RIF assay and microscopy for acid-fast bacilli. We discuss their respective merits and shortcomings and identify threats that may hamper their use in TB control. Neither test on its own provides all the information needed for diagnosis and treatment monitoring. Considering all aspects important for both individual patient care and disease control, neither seems 'better' than the other. The required advancement of microscopy had already been hampered before the introduction of the GeneXpert technology by unsuccessful and probably misguided attempts to decentralise culture-based diagnosis and drug susceptibility testing. It seems evident that systematic replacement of microscopy by Xpert is not a viable option for the foreseeable future. Instead, the two methods should complement each other to arrive at a comprehensive, accessible and continuous service for a maximum number of patients. This will intrinsically prioritise targeting the most potent transmitters with the worst prognosis, simultaneously offering optimised prospects for efficient TB control. New microscopy and Xpert applications are expected to ultimately make control programmes independent of culture-based methods in diagnosis, treatment monitoring and outcome assessment.